Results 91 to 100 of about 27,503 (257)

Dipeptidyl Peptidase-4 Inhibitor [PDF]

, 2020
openaire   +1 more source

Real‐World Cost and Utilisation Burden of Diagnosed Metabolic Dysfunction‐Associated Steatotic Liver Disease in Patients With Type 2 Diabetes in the United States: A Retrospective Cohort Study

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims This study quantified the real‐world healthcare costs and utilisation associated with diagnosed metabolic dysfunction‐associated steatotic liver disease (MASLD) among adults with Type 2 diabetes (T2D). Methods We conducted a retrospective cohort study using IQVIA PharMetrics Plus Closed Health Plan data from January 2016 to June 2025 ...
Tien Hoang Tran, Hyung‐Seok Kim, Rozalina G. McCoy, Zafar Zafari   +3 more
wiley   +1 more source

Oral Semaglutide in Routine Clinical Practice: 24‐Month Real‐World Effectiveness, Persistence and Safety in Adults With Type 2 Diabetes

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Real‐world long‐term data on oral semaglutide are limited. We evaluated its 24‐month effectiveness, persistence, and safety in adults with type 2 diabetes (T2D). Materials and Methods This retrospective real‐world study included 232 adults with T2D initiating oral semaglutide at an Italian diabetes clinic.
Maria Pompea Antonia Baldassarre, Giulia Di Dalmazi, Federica Carrieri, Giorgia Centorame, Luigi Piacentino, Sara Coluzzi, Gloria Formoso   +6 more
wiley   +1 more source

Genetics‐Informed Pharmacological Intervention in Gestational Diabetes Mellitus: Current Therapeutic Alignment, Emerging Targets and a Translational Roadmap

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Background Gestational diabetes mellitus (GDM) complicates roughly one in seven pregnancies and predicts later maternal type 2 diabetes mellitus (T2DM). Yet its pharmacological management still rests on a handful of agents (insulin, metformin and glibenclamide), none of them selected on the basis of the disease's molecular genetics.
Wael Osman
wiley   +1 more source

Severe edema and blood blisters of the lower extremities caused by sitagliptin, a dipeptidyl peptidase‐4 inhibitor

Journal of General and Family Medicine, 2022
Hiroki Maita, Tadashi Kobayashi, Takashi Akimoto, Hiroshi Osawa, Hiroyuki Kato   +4 more
doaj   +1 more source

The Ahlqvist Subphenotypes of Type 2 Diabetes: A Narrative Review of Scientific Evidence and Its Potential Contribution to Precision Diabetes

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Background Among several approaches, k‐means clustering has established as a widely used method to classify people with type 2 diabetes (T2D) into distinct subphenotypes, and the Ahlqvist T2D subphenotypes of Severe Insulin Deficient Diabetes (SIDD), Mild Age‐Related Diabetes (MARD), Mild Obesity Diabetes (MOD) and Severe Insulin Resistant ...
Wolfgang Landgraf, David R. Owens, Brian M. Frier, Geremia B. Bolli   +3 more
wiley   +1 more source

Heart Failure and Dipeptidyl Peptidase-4 Inhibitors [PDF]

European Journal of Heart Failure, 2014
Henry, Krum, Marina, Skiba, Shiying, Wu, Ingrid, Hopper   +3 more
openaire   +2 more sources

Comparative Effectiveness of GLP‐1RAs, SGLT2is and DPP4is for Cardiovascular Outcomes in Type 2 Diabetes: An Empirically Calibrated Target Trial Emulation Study

Diabetes, Obesity and Metabolism, EarlyView.
Bingyu Zhang, Ting Zhou, Huilin Tang, Yiwen Lu, Dazheng Zhang, Jiajie Chen, Tianchu Lyu, Kai Zheng, David A. Asch, Yong Chen   +9 more
wiley   +1 more source

Nutrient‐specific combinatorial secretion of GLP‐1 and neurotransmitters in the enteroendocrine L‐cell line GLUTag

The FEBS Journal, EarlyView.
Enteroendocrine L cells function as chemosensors in the intestine. Using the L‐cell line GLUTag, we show that distinct nutrients trigger different combinations of co‐secretion of GLP‐1 and neurotransmitters: D‐glucose evokes GLP‐1, glutamate, and ATP; L‐glutamine evokes GLP‐1 and glutamate; sucralose and butyrate evoke only GLP‐1.
Yo Ito, Kazuki Harada, Yuri Osuga‐Yoshiike, Masami Yokota Hirai, Tetsuya Kitaguchi, Takashi Tsuboi   +5 more
wiley   +1 more source

Saxagliptin for type 2 diabetes

Diabetes, Metabolic Syndrome and Obesity, 2010
Antonio R Chacra, MDDiabetes Center, Federal University of São Paulo, BrazilAbstract: Saxagliptin (Onglyza™) is a potent, selective, once-daily dipeptidyl peptidase-4 (DPP-4) inhibitor indicated for improving glycemic control in patients ...
Chacra
doaj   +2 more sources